Ipsen's Cabometyx Receives Health Canada's Approval for the Treatment of Advanced Renal Cell Carcinoma (RCC) in Adults
Shots:
- Approval of Cabometyx (cabozantinib) is based on results of the P-III METEOR trial assessing Cabometyx vs everolimus for advanced (RCC) previously received vascular endothelial growth factor (VEGF) targeted therapy- demonstrated significant and clinical improvement in OR- PFS- ORR
- Cabometyx received priority review status from Health Canada further assisted its approval. In 2017- the US FDA granted orphan drug designation to cabozantinib for the treatment of advanced HCC
- In 2016- Ipsen received exclusive rights from Exelixis- for commercialization and development of cabozantinib outside of the US and Japan
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
